Active Not Recruiting PHASE3 INTERVENTIONAL 2-arm NCT05505994

The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on Metformin

A Multi-center, Randomized, Double-Blind, Active-controlled, Phase 3, Therapeutic Confirmatory Study and Open-Label Extension Study to Evaluate the Efficacy and Safety of DWP16001 Add-on to Metformin in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin

Sponsor: Daewoong Pharmaceutical Co. LTD.

Conditions Diabetes Mellitus Diabetes Mellitus, Type 2 Endocrine System Diseases Glucose Metabolism Disorders Metabolic Disease

Interventions DWP16001 DWP16001 Placebo Dapagliflozin Dapagliflozin Placebo

Updated 4 times since 2022 Last updated: Apr 3, 2024 Started: Sep 28, 2022 Primary completion: Feb 26, 2024 Completion: Sep 30, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Diabetes Mellitus and Diabetes Mellitus, Type 2, this trial is ongoing. The trial is conducted by Daewoong Pharmaceutical Co. LTD. and has accumulated 4 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Active Not Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE3
May 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE3

Status: Not Yet Recruiting → Active Not Recruiting
Sep 2022 — May 2024 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Daewoong Pharmaceutical Co. LTD.

Data source: Daewoong Pharmaceutical Co. LTD.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China